drugset

drugset / Trial / NCT00891605

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

NCT00891605 ↗

Phase 1 Completed 19 enrolled AbbVie Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors.

Timeline

Start: 2009-07
Primary completion: 2012-07
Completion: 2012-07

Publications

Results Vlahovic G, Karantza V, Wang D, Cosgrove D, Rudersdorf N, Yang J, Xiong H, Busman T, Mabry M. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest New Drugs. 2014 Oct;32(5):976-84. doi: 10.1007/s10637-014-0116-3. Epub 2014 Jun 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Navitoclax	Small molecule	150 mg	Oral
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Indications